Point72 Europe’s Syndax Pharmaceuticals SNDX Stock Holding History

Point72 Europe’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-184,683	Closed	-$2.27M	–	193
2025 Q1	$2.27M	Buy	+184,683	New	+$2.6M	0.16%	111

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Point72 Europe's SNDX Position: Q2 2025 in Review

Point72 Europe sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 184,683 shares — an estimated $2.27M sold.

Point72 Europe first reported a position in SNDX in Q1 2025 and held it in 1 quarter. The position peaked at $2.27M in Q1 2025. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

Point72 Europe reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Point72 Europe sold 184,683 Syndax Pharmaceuticals shares in Q2 2025, an estimated $2.27M.
Point72 Europe first reported a position in Syndax Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Point72 Europe's Syndax Pharmaceuticals position peaked at $2.27M in Q1 2025.
216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Point72 Europe's 13F filing for Q2 2025, filed 14 Aug 2025.